Topical corticosteroid reforms adjuvant capecitabine chemotherapy. (T-CRACC STUDY)

Preventive effect of hydrocortisone topical for capecitabine related hand foot syndrome in patients with colorectal cancer undergoing adjuvant chemotherapy, a single center, single arm, phase 2 trial. - Topical corticosteroid reforms adjuvant capecitabine chemotherapy. (T-CRACC STUDY)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031220002

Enrollment

Registered

2022-04-05

Start date

2022-04-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer Colorectal cancer

Interventions

Administration of hydrocortisone topical

Medication

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Colorectal cancer patients undergoing adjuvant capecitabine and oxaliplatin therapy

Exclusion criteria

Exclusion criteria: Patients with contraindications for the administration of hydrocortisone topical

Design outcomes

Primary

Measure	Time frame
Frequency of occurrence of grade 2 or higher hand foot syndrome at the end of adjuvant chemotherapy (3 months after the start of adjuvant chemotherapy)	—

Secondary

Measure	Time frame
Time to onset of grade 2 or higher hand foot syndrome Time to onset of grade 1 or higher hand foot syndrome Dose reduction, postponement, and discontinuation rate	—

Contacts

Public ContactYohei Iimura

The IMSUT Hospital, The Institute of Medical Science, The University of Tokyo

iyouhei-tky@umin.ac.jp+81-3-3443-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026